Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

This Phase II study is testing a combination of drugs — glofitamab (a bispecific antibody that redirects the immune system to attack cancer), venetoclax (a targeted therapy), and optionally zanubrutinib (a BTK inhibitor) — for patients with high-risk mantle cell lymphoma, a type of blood cancer. **You may be eligible if...** - You have mantle cell lymphoma that is high-risk, has relapsed early, or has not responded to prior treatments including BTK inhibitors or CAR T-cell therapy (depending on which cohort you qualify for) - You have not previously been treated and have high-risk features (for cohort C) - CD20 expression is present on your cancer cells **You may NOT be eligible if...** - Your disease progressed while on both a BTK inhibitor and venetoclax at the same time - You have active brain involvement of lymphoma - You have uncontrolled infection or serious organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.